News

Experts continue to explore connections between sleep health and neurological disorders, as well as technology for measuring patients’ sleep.

The chief medical officer of Scholar Rock described how the investigational apitegromab aims to fill some of the current unmet needs for patients with spinal muscular atrophy.

The data suggest that women considered at high relapse risk or with poor prognostic factors benefit peripregnancy from high-efficacy therapy continuation.

Lucie Barateau, MD, assistant professor of neurology, Hôpital Gui De Chauliac, offered insight on the usefulness of the newly developed pediatric narcolepsy type 1 severity scale.

The associate professor of neurology at Washington University in St. Louis discussed how developing programs focused on sleep health are a step to increasing awareness and understanding its integral role in overall well-being.

Episode 12 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; Clifton L. Gooch, MD, of the University of South Florida; and Sharyl Martini, MD, PhD, of the VHA and Baylor College of Medicine. [WATCH TIME: 4 minutes]

Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.

Raman Malhotra, MD, associate professor of neurology at Washington University in St. Louis, commented on the importance of sleep education, particularly for younger generations.

Efficacy results from a 109-week interim analysis showed improvement for patients treated with viltolarsen when compared to the matched DMD historical control group.

ATH-1017, an investigational agent designed to focus on network recovery and synaptic signal transition in the brain, will be evaluated in patients on cognition, global, and functional assessments.

Raman Malhotra, MD, associate professor of neurology at Washington University in St. Louis, discussed the importance inquiring about patients’ sleep, as well as the dangers of insufficient sleep.

Here's what is coming soon to NeurologyLive.

Total lesion volume and index lesion-related severity correlated with EDSS scores and cognitive performance, while volumetric cortical and subcortical gray matter correlated less strongly.

Fabio Nascimento, MD, clinical fellow at Massachusetts General Hospital, spoke about his research on the alarming lack of knowledge on SUDEP and its risk factors among trainees.

Research into silent myocardial infarction may help identify cause of ischemic strokes that lack etiology, as well as identify better therapeutic strategies to combat recurring stroke.

Associate professor of neurology at Washington University in St. Louis discussed returning to normalcy following the COVID-19 pandemic and the nascent effects experts have seen on sleep health.

Neurology News Network for the week ending July 10, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 9, 2021.

Janet Woodcock, MD, acting commissioner of the FDA, called for an inquiry by the Office of the Inspector General into possible interactions between agency officials and Biogen that "may have occurred outside of the formal correspondence process."

Each of the 2 identical twin phase 3 trials, titled ENSURE-1 and ENSURE-2, are expected to enroll approximately 1050 adult patients with active relapsing multiple sclerosis.

Suggestions from Mary Anne Ehlert, founder and president, Protected Tomorrows, include getting involved with the community and making the most of benefits and programs.

The pediatric headache specialist at NYU Langone provided an inside perspective on the effect that societal stigmas have on those with pediatric migraine and how to address those stigmas.

The study was conducted at Wright-Patterson Air Force Base to examine the effect of fatigue on cognition and mood within the military population.  

Advocacy organization Cure SMA recap their recently concluded meeting, with notable presentations and medical education sessions led by world leaders.

Since 2016, there has been consistent growth in the number of Alzheimer disease trials sponsored both in part and fully by academic medical centers and/or the National Institutes of Health.

Raman Malhotra, MD, associate professor of neurology at Washington University in St. Louis, detailed a new position statement from AASM on the vitality of sleep.

The newly updated label language emphasizes the Alzheimer disease stages in which aducanumab was studied, with no additional changes made to its approval pathway.